<DOC>
	<DOC>NCT00799877</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).</brief_summary>
	<brief_title>Chronic Plaque Psoriasis (Ps) Registry</brief_title>
	<detailed_description>ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria: New initiated (within 4 weeks of registry entry) on HUMIRA® therapy; Initiated HUMIRA® therapy in the past and: Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy. OR Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of AbbVie sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug). 2. Patient is willing to consent to data being collected and provided to AbbVie; 3. Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry. 1. Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Severe Chronic Plaque Psoriasis</keyword>
	<keyword>Registry</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Moderate Psoriasis</keyword>
</DOC>